Aurora Cannabis Inc., the Canadian based leading global medical cannabis company, is pleased to announce today that Simona King, a former executive of Bristol Myers-Squibb, a leading multinational pharmaceutical company, has been appointed as Chief Financial Officer of the Company, effective February 21, 2024. Ms. King brings over 25 years of progressive finance leadership experience, with deep business knowledge and proven success with global and emerging organizations. She served nearly 20 years with Bristol Myers-Squibb, where she held increasingly senior finance roles and enabled the company’s growth strategy.
Glen Ibbott, current Chief Financial Officer, will be stepping down from his full-time role effective today to pursue new opportunities. He will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Simona.
CFO Transition
“As our company continues to evolve, we are thrilled to welcome Simona King to Aurora. Simona has spent her career growing businesses, improving operational efficiencies, and leading a best- in-class global financial organization. Her deep operational and financial knowledge, combined with her extensive experience across many corporate functions and deep commitment to developing talent, make her uniquely positioned to help lead Aurora into its next phase of growth” said Miguel Martin, CEO.
Mr. Martin continued, “On behalf of our Board of Directors, and the entire Aurora team, I would like to offer our sincere thanks and appreciation to Glen. Since 2017, Glen has dedicated immeasurable time, energy, and passion to shaping Aurora into a leading medical cannabis company; and we have been fortunate to have his leadership over the years as we navigated this emerging industry. We wish him all the best for his future endeavours.”
Ms. King brings deep financial expertise across corporate, operations and international business units. In recent years, she has spread her professional reach, joining fast moving public companies in emerging sectors, including biotech. She joins Aurora most recently as the CFO of a number of clinical stage biotechnology companies.
Share Consolidation
Aurora also announces the completion of its previously announced consolidation of the common shares of the Company (the “Common Shares“) on a 10 to 1 basis (the “Consolidation“). The Common Shares will begin trading on a post-Consolidation basis on the NASDAQ Capital Market (the “NASDAQ“) and the Toronto Stock Exchange (the “TSX“) under the symbol “ACB” at the opening of trading today.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company’s adult- use brand portfolio includes Aurora Drift, San Rafael ’71, Daily Special, Tasty’s, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Learn more at www.auroramj.com and follow us on X and LinkedIn.
